Skip to main content
. 2020 Jun 15;201(12):1488–1498. doi: 10.1164/rccm.201906-1215OC

Figure 2.

Figure 2.

Difference in the area under the logarithm level of urinary biomarker concentration versus time curve (AUC(Before-24 h)) and levels of urinary LTE4 and tetranor-PGDM concentrations during oral aspirin challenge between the placebo and omalizumab phases. (A) AUC[Before-24 h] of LTE4. (B) AUC[Before-24 h] of tetranor-PGDM. (C and D) Time course of log-transformed levels of urinary LTE4 (C) and tetranor-PGDM (D) concentrations. Wilcoxon signed-rank test. *P < 0.05 and **P < 0.01. The log-transformed urinary LTE4 and tetranor-PGDM concentrations are expressed as medians and interquartile ranges. LTE4 = leukotriene E4; tetranor-PGDM = 11,15-dioxo-9α-hydroxy-2,3,4,5-tetranorprostan-1,20-dioic acid.